Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt (Tables)

v3.19.3
Long-Term Debt (Tables)
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of September 30, 2019, are as follows (in thousands):

 

Three months ending December 31, 2019

$

1,146

 

Year ending December 31, 2020

 

6,086

 

Year ending December 31, 2021

 

8,576

 

Year ending December 31, 2022

 

21,950

 

Thereafter

 

-

 

Total payments

 

37,758

 

Less: interest, final payment fees, discount and issuance cost

 

(5,079

)

Total payments, net of interest, final payment fees, discount and issuance cost

 

32,679

 

Less: current portion of long-term debt

 

(3,981

)

Long-term debt

$

28,698

 

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive income (loss) relates to the following debt instruments (in thousands):

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

SVB loans

$

314

 

 

$

35

 

 

$

791

 

 

$

47

 

Novartis note

 

168

 

 

 

171

 

 

 

540

 

 

 

453

 

Other

 

2

 

 

 

3

 

 

 

5

 

 

 

57

 

Total interest expense

$

484

 

 

$

209

 

 

$

1,336

 

 

$

557